Cargando…

SNCA Rep1 microsatellite length influences non-motor symptoms in early Parkinson’s disease

Long alpha-synuclein gene (SNCA) promoter (Rep1) allele-carriers are linked to higher risk for Parkinson’s disease (PD) and faster motor progression. Non-motor symptoms including autonomic, neuropsychiatric, and sleep disorders are common in PD. However, the relationship between SNCA Rep1 microsatel...

Descripción completa

Detalles Bibliográficos
Autores principales: Yong, Alisa CW, Tan, Yi Jayne, Zhao, Yi, Lu, Zhonghao, Ng, Ebonne YL, Ng, Samuel YE, Chia, Nicole SY, Choi, Xinyi, Heng, Dede, Neo, Shermyn, Xu, Zheyu, Tay, Kay Yaw, Au, Wing Lok, Tan, Eng-King, Tan, Louis CS, Ng, Adeline SL
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655210/
https://www.ncbi.nlm.nih.gov/pubmed/33082300
http://dx.doi.org/10.18632/aging.104111
Descripción
Sumario:Long alpha-synuclein gene (SNCA) promoter (Rep1) allele-carriers are linked to higher risk for Parkinson’s disease (PD) and faster motor progression. Non-motor symptoms including autonomic, neuropsychiatric, and sleep disorders are common in PD. However, the relationship between SNCA Rep1 microsatellite lengths and non-motor symptoms in early PD remains to be elucidated. 171 consecutive early PD patients were recruited from tertiary clinics and genotyped for Rep1. Multivariable regression analyses were performed to examine associations between Rep1 alleles and non-motor outcome scores. Longer Rep1 alleles significantly associated with higher total Non-Motor Symptom Scale (NMSS) scores (p=.006) and Hospital Anxiety and Depression Scale (HADS) depression subscale scores (p=.002), after adjusting for covariates and Bonferroni correction. We demonstrated that SNCA Rep1 allele length influences overall non-motor symptom burden and depression in early PD patients. Further functional studies to evaluate the role of Rep1 in non-dopaminergic systems may unravel new therapeutic targets for non-motor symptoms in PD.